STB
SUPN icon

S&T Bank’s Supernus Pharmaceuticals SUPN Stock Holding History

S&T Bank’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.71M Sell
52,485
-22,639
-30% -$1.15M 1.01% 30
2025
Q4 		$3.73M Sell
75,124
-13,791
-16% -$671K 1.18% 29
2025
Q3 		$4.25M Sell
88,915
-18,506
-17% -$745K 1.19% 34
2025
Q2 		$3.39M Sell
107,421
-3,656
-3% -$117K 1.03% 38
2025
Q1 		$3.64M Sell
111,077
-1,110
-1% -$39.3K 1.19% 33
2024
Q4 		$4.06M Sell
112,187
-11,146
-9% -$392K 1.29% 34
2024
Q3 		$3.85M Sell
123,333
-4,303
-3% -$134K 1.01% 41
2024
Q2 		$3.41M Sell
127,636
-47,928
-27% -$1.39M 0.87% 48
2024
Q1 		$5.99M Sell
175,564
-13,792
-7% -$411K 1.15% 42
2023
Q4 		$5.48M Sell
189,356
-26,222
-12% -$695K 1.01% 44
2023
Q3 		$5.94M Sell
215,578
-5,665
-3% -$172K 1.15% 41
2023
Q2 		$6.65M Sell
221,243
-2,532
-1% -$88.6K 1.2% 41
2023
Q1 		$8.11M Sell
223,775
-65,494
-23% -$2.52M 1.46% 34
2022
Q4 		$10.3M Sell
289,269
-11,957
-4% -$416K 1.9% 16
2022
Q3 		$10.2M Sell
301,226
-12,164
-4% -$396K 1.97% 16
2022
Q2 		$9.06M Sell
313,390
-2,936
-0.9% -$84.1K 1.59% 25
2022
Q1 		$10.2M Sell
316,326
-243
-0.1% -$7.45K 1.54% 26
2021
Q4 		$9.23M Buy
316,569
+471
+0.1% +$14.3K 1.35% 32
2021
Q3 		$8.43M Sell
316,098
-2,584
-0.8% -$69.4K 1.31% 34
2021
Q2 		$9.81M Sell
318,682
-851
-0.3% -$26.1K 1.52% 26
2021
Q1 		$8.37M Sell
319,533
-611
-0.2% -$17.1K 1.36% 31
2020
Q4 		$8.05M Buy
320,144
+406
+0.1% +$8.74K 1.45% 33
2020
Q3 		$6.66M Buy
319,738
+18,852
+6% +$428K 1.52% 30
2020
Q2 		$7.15M Sell
300,886
-4,628
-2% -$102K 1.63% 28
2020
Q1 		$5.5M Buy
305,514
+51,659
+20% +$1.09M 1.51% 29
2019
Q4 		$6.02M Buy
253,855
+1,532
+0.6% +$37.2K 1.23% 37
2019
Q3 		$6.94M Buy
252,323
+9,764
+4% +$289K 1.5% 32
2019
Q2 		$8.03M Buy
242,559
+79,525
+49% +$2.72M 1.76% 23
2019
Q1 		$5.71M Buy
+163,034
New +$6.07M 1.29% 39

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

S&T Bank's SUPN Position: Q1 2026 in Review

S&T Bank reduced its Supernus Pharmaceuticals (SUPN) stake by 30% in Q1 2026, selling an estimated $1.15M and leaving 52,485 shares worth $2.71M. The position accounts for 1.01% of the portfolio, ranked #30.

S&T Bank first reported a position in SUPN in Q1 2019 and has held it in 29 quarters since. The position peaked at $10.3M in Q4 2022. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • S&T Bank held 52,485 shares of Supernus Pharmaceuticals worth $2.71M as of Q1 2026.
  • S&T Bank sold 22,639 Supernus Pharmaceuticals shares in Q1 2026, an estimated $1.15M.
  • Supernus Pharmaceuticals made up 1.01% of S&T Bank's portfolio in Q1 2026, its #30 holding.
  • S&T Bank first reported a position in Supernus Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • S&T Bank's Supernus Pharmaceuticals position peaked at $10.3M in Q4 2022.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on S&T Bank's 13F filing for Q1 2026, filed 13 May 2026.